Loading...
Loading...
GRCL| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 145.8M |
| Operating I/L | -145.8M |
| Other Income/Expense | -0.5M |
| Interest Income | 2.7M |
| Pretax | -146.3M |
| Income Tax Expense | -1.2M |
| Net Income/Loss | -145.1M |
Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company based in China. The company focuses on discovering and developing cell therapies for the treatment of cancer. Its lead product candidates include CAR-T cell therapies targeting multiple myeloma, B cell acute lymphoblastic leukemia, and adult T cell acute lymphoblastic leukemia. Gracell also has a portfolio of earlier stage product candidates targeting various cancer indications. The company generates revenue through the development and potential commercialization of its cell therapy products for cancer treatment.
